E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 1/20/2006 in the Prospect News Biotech Daily.

Wyeth reiterated by Bear Stearns at outperform

Bear Stearns analyst John T. Boris reiterated Wyeth at an outperform rating. Wyeth offers an attractive 10%, five-year earnings per share CAGR at a 7% discount to the broader market. Bear Stearns expects Wyeth to report in line with consensus and the analyst's estimate of $0.61. Shares of the Madison, N.J., pharmaceutical company were down $1.21, or 2.52%, at $46.77 on volume of 4,573,800 shares versus the three-month running average of 5,280,190 shares. (NYSE: WYE)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.